ECSP12011910A - Derivados de imidazopiridina como inhibidores de jak - Google Patents

Derivados de imidazopiridina como inhibidores de jak

Info

Publication number
ECSP12011910A
ECSP12011910A ECSP12011910A ECSP12011910A EC SP12011910 A ECSP12011910 A EC SP12011910A EC SP12011910 A ECSP12011910 A EC SP12011910A EC SP12011910 A ECSP12011910 A EC SP12011910A
Authority
EC
Ecuador
Prior art keywords
derivatives
imidazopiridine
jak inhibitors
jak
inhibitors
Prior art date
Application number
Other languages
English (en)
Inventor
Paul Robert Eastwood
Santacana Luis Miguel Pages
Moll Joan Taltavull
Rodriguez Jacob Gonzalez
TAÑA Jordi BACH
Javaloyes Juan Francisco Caturla
Victor Giulio Matassa
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42136251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12011910(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of ECSP12011910A publication Critical patent/ECSP12011910A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen nuevos derivados de imidazopiridina que tiene la estructura química de fórmula (I); así como un procedimiento para su preparación y composiciones farmacéuticas que los comprenden como inhibidores de quinasas Janus (JAK).
ECSP12011910 2009-12-24 2012-05-27 Derivados de imidazopiridina como inhibidores de jak ECSP12011910A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382303A EP2338888A1 (en) 2009-12-24 2009-12-24 Imidazopyridine derivatives as JAK inhibitors
US29029309P 2009-12-28 2009-12-28

Publications (1)

Publication Number Publication Date
ECSP12011910A true ECSP12011910A (es) 2012-07-31

Family

ID=42136251

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011910 ECSP12011910A (es) 2009-12-24 2012-05-27 Derivados de imidazopiridina como inhibidores de jak

Country Status (26)

Country Link
US (1) US20130216498A1 (es)
EP (2) EP2338888A1 (es)
JP (1) JP2013515688A (es)
KR (1) KR20120118459A (es)
CN (1) CN102695706A (es)
AR (1) AR079689A1 (es)
AU (1) AU2010335556A1 (es)
BR (1) BR112012015540A2 (es)
CA (1) CA2785113A1 (es)
CL (1) CL2012001379A1 (es)
CO (1) CO6541643A2 (es)
CR (1) CR20120334A (es)
EA (1) EA201200938A1 (es)
EC (1) ECSP12011910A (es)
GT (1) GT201200207A (es)
IL (1) IL219916A0 (es)
MX (1) MX2012007175A (es)
NZ (1) NZ599932A (es)
PE (1) PE20121482A1 (es)
PH (1) PH12012501164A1 (es)
SG (2) SG10201407927UA (es)
TW (1) TWI481608B (es)
UA (1) UA107951C2 (es)
UY (1) UY33130A (es)
WO (1) WO2011076419A1 (es)
ZA (1) ZA201203326B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
CA2791020A1 (en) * 2010-04-28 2011-11-03 Daiichi Sankyo Company, Limited [5,6] heterocyclic compound
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
WO2012143796A2 (en) * 2011-04-21 2012-10-26 Institut Pasteur Korea Anti-inflammation compounds
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
RU2644769C2 (ru) 2013-01-23 2018-02-14 Астразенека Аб Химические соединения
HUE051195T2 (hu) * 2013-03-14 2021-03-01 Galapagos Nv Új vegyületek és gyógyászati készítményeik gyulladásos rendellenességek kezelésére
TW201605832A (zh) * 2013-12-10 2016-02-16 克立弗生物科學公司 作為ｐ９７錯合物之抑制劑之單環嘧啶／吡啶化合物
WO2015091531A1 (en) * 2013-12-19 2015-06-25 Almirall, S.A. Imidazolopyrimidin-2-yl derivatives as jak inhibitors
AU2015206292B2 (en) 2014-01-20 2018-02-15 Cleave Biosciences, Inc. Fused pyrimidines as inhibitors of p97 complex
WO2015138273A1 (en) * 2014-03-13 2015-09-17 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
TWI679205B (zh) 2014-09-02 2019-12-11 日商日本新藥股份有限公司 吡唑并噻唑化合物及醫藥
FR3030521B1 (fr) * 2014-12-23 2019-07-26 Galderma Research & Development Nouveaux composes heterocycliques et leur utilisation en medecine ainsi qu'en cosmetique
CN107428749B (zh) 2015-01-28 2020-07-24 上海复旦张江生物医药股份有限公司 取代的咪唑并[1,2-α]吡啶-2-基胺化合物及其药物组合物和使用方法
TW201705961A (zh) 2015-06-11 2017-02-16 阿爾米雷爾有限公司 作為ｊａｋ抑制劑的２－（吡唑并吡啶－３－基）嘧啶衍生物
KR20180073687A (ko) 2015-11-03 2018-07-02 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 호흡기 질환의 치료를 위한 jak 키나제 저해제 화합물
TWI712604B (zh) 2016-03-01 2020-12-11 日商日本新藥股份有限公司 具jak抑制作用之化合物之結晶
MA45244A (fr) 2016-06-13 2019-04-17 Cancer Research Tech Ltd Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
AU2018231032B2 (en) 2017-03-09 2021-08-19 Theravance Biopharma R&D Ip, Llc JAK inhibitors containing a 4-membered heterocyclic amide
KR102568333B1 (ko) 2017-05-01 2023-08-18 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 저해제 화합물을 사용하는 치료 방법
JP7377207B2 (ja) * 2018-01-29 2023-11-09 メルク パテント ゲーエムベーハー Ｇｃｎ２阻害剤およびその使用
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
WO2020116296A1 (ja) * 2018-12-07 2020-06-11 ユニマテック株式会社 含フッ素ピリミジン化合物およびその製造方法
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR102894509B1 (ko) 2019-07-24 2025-12-02 메르크 파텐트 게엠베하 4-(이미다조[1,2-a]피리딘-3-일)-피리미딘 유도체
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
JP7109684B2 (ja) 2019-11-01 2022-07-29 ユニマテック株式会社 含フッ素ピリミジン化合物およびその製造方法
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20230096085A1 (en) * 2020-02-12 2023-03-30 Unimatec Co., Ltd. Fluorine-containing pyrimidine compound and production method therefor
US12503457B2 (en) 2020-03-25 2025-12-23 Unimatec Co., Ltd. Fluorine-containing pyrimidine compound, and method for producing same
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
CN115551840B (zh) 2020-05-19 2024-12-03 优迈特株式会社 含氟嘧啶化合物和含氟嘧啶酮化合物
TW202317550A (zh) 2021-06-25 2023-05-01 美商施萬生物製藥研發 Ip有限責任公司 作為jak抑制劑之咪唑吲唑化合物
CA3226908A1 (en) * 2021-07-30 2023-02-02 Scott Bryan HOYT Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
CN115724839A (zh) * 2021-08-26 2023-03-03 科辉智药生物科技(深圳)有限公司 Sarm1酶活性抑制剂及其应用
IL316619A (en) * 2022-05-10 2024-12-01 Relay Therapeutics Inc PI3Kα inhibitors and methods of using them
AU2023283393A1 (en) * 2022-06-10 2025-01-02 Interline Therapeutics, Inc. Imidazo(1,2-a)pyridine derivatives as ripk2 inhibitors
WO2024119067A1 (en) 2022-12-02 2024-06-06 Neumora Therapeutics, Inc. Methods of treating neurological disorders
WO2026048597A1 (ja) * 2024-08-27 2026-03-05 ユニマテック株式会社 含フッ素ピリミジン化合物、含フッ素ピリミジノン化合物および殺菌剤

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54128591A (en) 1978-03-25 1979-10-05 Kyowa Hakko Kogyo Co Ltd Cephalosporin analog
JP3299971B2 (ja) 1995-06-21 2002-07-08 アスタ メディカ アクチエンゲゼルシャフト 一体的に形成された調量装置を備えた薬用粉末カートリッジおよび粉末薬剤吸入器
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
JP4310109B2 (ja) * 2001-04-26 2009-08-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾリル基を置換基として有する含窒素縮合環化合物およびその医薬組成物
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
CA2450555A1 (en) * 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
EP1503757B1 (en) * 2002-05-02 2007-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
AUPS251402A0 (en) * 2002-05-23 2002-06-13 Cytopia Pty Ltd Kinase inhibitors
NZ537155A (en) 2002-05-23 2006-09-29 Cytopia Pty Ltd Protein kinase inhibitors
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
CA2549485A1 (en) 2003-12-17 2005-07-07 Pfizer Products Inc. Pyrrolo [2,3-d] pyrimidine compounds for treating transplant rejection
DE102004012070A1 (de) 2004-03-12 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue cycloalkyl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
US7507826B2 (en) * 2004-03-30 2009-03-24 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of JAK and other protein kinases
EP1753748B1 (en) 2004-05-12 2009-07-29 Pfizer Products Inc. Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
WO2006038001A1 (en) * 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
PL2383268T3 (pl) 2005-02-04 2016-02-29 Astrazeneca Ab Pochodne pirazoliloaminopirydyny użyteczne jako inhibitory kinazy
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2296516B1 (es) 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ATE476418T1 (de) 2006-06-08 2010-08-15 Amgen Inc Benzamidderivate und assoziierte verwendungen
CL2007002867A1 (es) 2006-10-04 2008-06-27 Pharmacopeia Inc Compuestos derivados de 2-(bencimidazolil)purina, inhibidores de janus quinasa 3; composicion farmaceutica que los contiene; y su uso para tratar enfermedades autoinmune, inflamatorias, cardiovasculares, rechazo de implante, entre otras.
ATE542818T1 (de) * 2006-10-11 2012-02-15 Amgen Inc Imidazo- und triazolopyridinverbindungen und verfahren zu deren anwendung
ES2302447B1 (es) 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
JP5442449B2 (ja) * 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
ES2306595B1 (es) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
ES2400604T3 (es) * 2007-08-17 2013-04-11 Icagen, Inc. Heterociclos como moduladores del canal de potasio
US8183245B2 (en) * 2007-10-25 2012-05-22 Merck Sharp & Dohme Corp. Pyrazine substituted pyrrolopyridines as inhibitors of JAK and PDK1
EP2252618A1 (en) * 2007-12-19 2010-11-24 Vertex Pharmaceuticals Incorporated PYRAZOLO [1,5-a] PYRIMIDINES USEFUL AS JAK2 INHIBITORS
BRPI0822237A2 (pt) * 2007-12-21 2015-06-30 Wyeth Llc Compostos de imidazo [1,2-a] piridina
KR101261514B1 (ko) * 2008-02-25 2013-05-07 에프. 호프만-라 로슈 아게 피롤로피라진 키나아제 저해제
FR2928150A1 (fr) 2008-02-29 2009-09-04 Vetoquinol Sa Sa Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens
ES2605815T3 (es) 2008-07-01 2017-03-16 Ptc Therapeutics, Inc. Moduladores de la expresión de la proteína Bmi-1
JP5576370B2 (ja) * 2008-08-06 2014-08-20 ファイザー・インク Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物

Also Published As

Publication number Publication date
IL219916A0 (en) 2012-07-31
ZA201203326B (en) 2013-03-27
SG10201407927UA (en) 2015-01-29
EA201200938A1 (ru) 2013-02-28
JP2013515688A (ja) 2013-05-09
UA107951C2 (xx) 2015-03-10
UY33130A (es) 2011-06-30
US20130216498A1 (en) 2013-08-22
GT201200207A (es) 2015-02-19
CN102695706A (zh) 2012-09-26
KR20120118459A (ko) 2012-10-26
CA2785113A1 (en) 2011-06-30
PE20121482A1 (es) 2012-11-05
EP2338888A1 (en) 2011-06-29
AU2010335556A1 (en) 2012-05-31
SG181439A1 (en) 2012-07-30
AR079689A1 (es) 2012-02-15
CL2012001379A1 (es) 2012-10-12
TWI481608B (zh) 2015-04-21
BR112012015540A2 (pt) 2019-09-24
PH12012501164A1 (en) 2017-08-23
NZ599932A (en) 2014-08-29
EP2516436A1 (en) 2012-10-31
CR20120334A (es) 2012-10-05
WO2011076419A1 (en) 2011-06-30
TW201130835A (en) 2011-09-16
MX2012007175A (es) 2012-07-04
CO6541643A2 (es) 2012-10-16

Similar Documents

Publication Publication Date Title
CO6541643A2 (es) Derivados de imidazopirina como inhibidores de jak
CR20120634A (es) Derivados de heteroaril imidazolona como inhibidores de jak
CR20120427A (es) Derivados de pirazol como inhibidores de jak
CR20140031A (es) Derivados de piridin-2(1h)-ona como inhibidores de jak
ECSP11011183A (es) Compuestos orgánicos
ECSP11011184A (es) Compuestos orgánicos
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
CO6362015A2 (es) Derivados de acido 1-amino-2ciclobutiletilboronico
UY35467A (es) Compuestos orgánicos
CR20130543A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
UY30444A1 (es) Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos.
ECSP11011347A (es) Nicotinamida sustituida como moduladores KCNQ2/3
CU23761B7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CR20110703A (es) Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt(pkb)
ECSP10010200A (es) Derivados de pirazol como inhibidores de 5-lo
UY32635A (es) Derivados de bis-(sulfonilamino) en terapia 735
UY35876A (es) Derivados de pirazolopirimidin-2-ilo como inhibidores de jak
CR20120109A (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY32415A (es) NUEVOS DERIVADOS DE TETRAHIDROPIRAZOLO[3,4-c]ISOQUINOLIN-5-AMINA
NI201300028A (es) Nuevos derivados dihidrobenzoxatiazepinas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
CR20110647A (es) 17ß-ALQUIL-17a-OXY-ESTRATIENOS
ECSP10010292A (es) Nuevos derivados de ácido 2-mercaptociclopentanocarboxílico, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CU20100105A7 (es) Derivados de pirazol como inhibidores de 5-lo
CU20070102A7 (es) Derivados de quinolina e isoquinolina 5-sustituidos, un procedimiento para su preparación y su uso como inhibidores de la inflamación